Trial Profile
Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maintenance Treatment and Reinduction in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluoropyrimidine derivatives; Fluorouracil; Folic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 20 Jul 2018 Results published in the European Journal of Cancer
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results of pooled analysis of AIO KRK 0207 and RO91 trials presented at the 53rd Annual Meeting of the American Society of Clinical Oncology